AstraZeneca’s China partner expects to be able to make 400 mln COVID-19 vaccine doses a year

BEIJING: China’s Shenzhen Kangtai Biological Products said on Tuesday it had completed a facility designed to be able to produce 400 million doses of AstraZeneca’s COVID-19 vaccine per year, doubling a capacity target promised in 2020.
“Kangtai is actively pushing forward procedures for the vaccine’s clinical trial and registration in China, and has completed a manufacturing plant and started trial production,” the Shenzhen-based firm said in a press release.